[PDF][PDF] Research Article Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries …

A Inotai, M Csanadi, G Petrova, M Dimitrova… - 2018 - academia.edu
This policy research aims to map patient access barriers to biologic treatments, to explore
how increased uptake of biosimilars may lower these hurdles and to identify factors limiting …

[图书][B] Cost-effectiveness modelling for benefit-risk assessment

HJ Catt - 2018 - search.proquest.com
Introduction and aims: Benefit-risk assessment is important for summarising the
effectiveness and safety profile of an intervention. Current methods for benefit-risk …

Therapeutic Drug Monitoring of Biologic Agents

FI Scott, MT Osterman - Treatment of Inflammatory Bowel Disease with …, 2018 - Springer
Monoclonal antibodies directed against tumor necrosis factor (TNF)-α have markedly
impacted the course of Crohn's disease and ulcerative colitis. However, it was recognized …

[PDF][PDF] Apport des biosimilaires et des nouvelles biothérapies dans le traitement des maladies inflammatoires chroniques de l'intestin

F Carbonnel - fmcgastro.org
Les anti-TNF sont des médicaments efficaces dans le traitement d'induction et d'entretien
des maladies inflammatoires chroniques de l'intestin (MICI). Ils ont reçu une autorisation de …

[引用][C] Vpliv azatioprina in metotreksata na farmakokinetiko in učinkovitost infliksimaba pri zdravljenju Crohnove bolezni:[doktorsko delo]

D Drobne - 2016 - repozitorij.uni-lj.si
METODE: Vključili smo 223 prospektivno spremljanih bolnikov s Crohnovo boleznijo v
univerzitetni bolnišnici v Leuvnu, v Belgiji. 158 bolnikov je prejemalo kombinirano …